Efficacy & Safety of Minoxidil SL Tablets in Men With AGA

Inclusion Criteria: * Cisgender males of at least 18 years of age (inclusive) at the time of Screening. * In good general health in the opinion of the Investigator. * Presence of androgenetic alopecia with hair density reduction in the centroparietal area or vertex of the scalp classified as Norwood-Hamilton Type III vertex, IV, V or VI. * Willing and able to attend all study visits and comply with treatment plan and required study procedures including scalp tattooing and hair trimming. * Willing to maintain the same hair style, hair colour, and hair length in non-balding areas. * Able to comprehend and willing to sign and date a written patient informed consent form (PICF). Exclusion Criteria: * Norwood-Hamilton Type IIIa, IVa, and Va grades (i.e. participants must have vertex balding). * Use of topical minoxidil, oral minoxidil, dutasteride, finasteride, drugs with anti-androgenetic or androgenetic properties, or medications that cause hypertrichosis or hypotrichosis within the 6 months prior to enrolment. * Laser treatment of the scalp within 3 months prior to enrolment. * History of scalp micropigmentation or hair restoration surgery. * Use of wigs, hair extensions, hair pieces, or hair weaves at time of enrolment. * Use of anti-hypertensive medication. * Current participation in any other investigational drug or medical device trial, which includes administration of an investigational study medication or medical device, or participation in such a trial within 3 months…